Answers are grounded in this paper and cite their sources.
Reveals NF-κB activation predicts immunotherapy response in solid tumors, suggesting a biomarker for therapy efficacy.
Cancer immunotherapy improves survival, yet many patients exhibit primary or acquired resistance. We established a combinatorial immunotherapy (COMBO) consisting of tumor antigen-specific Th1 cells and dual immune checkpoint blockade and aimed to noninvasively identify sites of immune activation associated with therapeutic response. Using NF-κB Luc-reporter mice, we longitudinally monitored NF-κB activation by using in vivo bioluminescence imaging in the tumor microenvironment (TME) and bone marrow (BM) of mice bearing OVA-expressing MC38 adenocarcinoma (responder) or B16 melanoma (non-responder). COMBO treatment induced tumor regression in OVA-MC38 but not OVA-B16 tumors. Responsive tumors showed significantly increased NF-κB activation in the TME, whereas resistant melanomas displayed no therapy-induced NF-κB activation. In contrast, BM NF-κB activity was reduced upon COMBO treatment in both models. Immunofluorescence and flow cytometry analyses revealed NF-κB activation in tumor-infiltrating MPO⁺ neutrophils and a concomitant reduction of CD11b⁺Gr-1 high neutrophils in the BM in OVA-MC38 bearing mice, suggesting therapy-driven myeloid cell egress. Thus, therapeutic efficacy strongly correlated with NF-κB activation within the TME, while systemic BM changes reflected immune mobilization. Longitudinal imaging of NF-κB activity may enable early discrimination between therapy-sensitive and -resistant tumors in preclinical models.
No takes yet. Share an insight, caveat, or question.
Stowbur et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: